Findings

What do systematic reviews say?

358 questions · 360 findings · 31 reviews · Vascular

Sort:Best matchNewest Highest certainty Download CSV

No studies found 86 · 23.9%GRADE not reported 15 · 4.2%Very low 40 · 11.1%Low 117 · 32.5%Moderate 90 · 25%High 12 · 3.3%

Lanadelumab vs placebo or active control

Disability standardised mean difference (lower is better) (during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 64 participants
Low

Lanadelumab vs placebo or active control

Adverse events(during · children or adults with Types I or II HAE

Lanadelumab showed no clear difference in adverse events(during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 1.07 [0.77, 1.47]
2 studies · 158 participants
Low

Avoralstat vs placebo

Quality of lifeAngioedema Quality of Life scale (lower score is better)(during · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 93 participants
Moderate

Avoralstat vs placebo

Disability (any validated scale) (during · children or adults with Types I or II HAE

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Avoralstat vs placebo

Adverse events (during · children or adults with Types I or II HAE

Avoralstat showed no clear difference in adverse events (during compared with placebo (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.85 [0.62, 1.16]
1 study · 24 participants
Low

Berotralstat vs placebo or active control

Risk of HAE attacks (during · children or adults with Types I or II HAE

Berotralstat showed no clear difference in risk of HAE attacks (during compared with placebo or active control (low certainty).

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
RR 0.63 [0.39, 1]
1 study · 37 participants
Low

Berotralstat vs placebo or active control

Change in number of HAE attacks (per week) · children or adults with Types I or II HAE

1 finding from 1 review

Interventions for the long‐term prevention of hereditary angioedema attacks 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 130 participants
Low

Foam sclerotherapy vs placebo

Cosmetic appearance · participants with varicose veinsa

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 223 participants
Very low

Foam sclerotherapy vs placebo

Complications ‐ DVT · participants with varicose veinsa

It is very uncertain whether foam sclerotherapy changes complications ‐ DVT compared with placebo (very low certainty).

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
RR 5.1 [1.3, 20.01]
3 studies · 302 participants
Very low

Foam sclerotherapy vs placebo

Residual varicose veins · participants with varicose veinsa

It is very uncertain whether foam sclerotherapy changes residual varicose veins compared with placebo (very low certainty).

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
RR 0.19 [0.13, 0.29]
2 studies · 225 participants
Very low

Foam sclerotherapy vs placebo

QoL · participants with varicose veinsa

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 299 participants
Very low

Foam sclerotherapy vs placebo

Persistence of symptoms · participants with varicose veinsa

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 223 participants
Low

Foam sclerotherapy vs placebo

Recurrent varicose veins · participants with varicose veinsa

The review found no eligible studies for this question.

1 finding from 1 review

Injection sclerotherapy for varicose veins 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Aspirin vs placebo

Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous fistula or graft

Aspirin showed no clear difference in graft thrombosis (28 days to 18 months) compared with placebo (low certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.4 [0.07, 2.25]
3 studies · 175 participants
Low

Dipyridamole vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole vs placebo

Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Low

Dipyridamole vs placebo

Number of related surgical or radiological interventions · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole plus aspirin vs placebo

Graft thrombosis (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

Dipyridamole plus aspirin showed no clear difference in graft thrombosis (up to 18 months) compared with placebo (moderate certainty).

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
OR 0.64 [0.16, 2.56]
1 study · 41 participants
Moderate

Dipyridamole plus aspirin vs placebo

Length of hospital stay · people with ESRD receiving haemodialysis through an arteriovenous graft

The review found no eligible studies for this question.

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Dipyridamole plus aspirin vs placebo

Complications (up to 18 months) · people with ESRD receiving haemodialysis through an arteriovenous graft

1 finding from 1 review

Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 41 participants
Low